Shares of Kenvue Inc. (NYSE:KVUE – Get Free Report) have earned an average rating of “Hold” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $25.33.
Several equities analysts have recently commented on the stock. Barclays upped their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Monday, May 12th. Citigroup reiterated a “neutral” rating on shares of Kenvue in a research report on Friday, June 13th. UBS Group raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Friday, May 9th. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Finally, Redburn Atlantic assumed coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective for the company.
Read Our Latest Stock Analysis on KVUE
Hedge Funds Weigh In On Kenvue
Kenvue Stock Up 0.1%
Shares of NYSE:KVUE opened at $21.39 on Wednesday. The stock has a market capitalization of $41.03 billion, a price-to-earnings ratio of 38.88, a price-to-earnings-growth ratio of 3.32 and a beta of 0.98. Kenvue has a 1-year low of $17.67 and a 1-year high of $25.17. The company’s fifty day moving average is $23.00 and its two-hundred day moving average is $22.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86.
Kenvue (NYSE:KVUE – Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm’s revenue was down 3.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.28 earnings per share. Equities analysts anticipate that Kenvue will post 1.14 EPS for the current year.
Kenvue Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date was Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is 149.09%.
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- Why Invest in 5G? How to Invest in 5G Stocks
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Overheated Market? Analysts Watch These Red Flags
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.